What is the latest MOREPENLAB stock price?
The latest stored price for MOREPENLAB is Rs 58.23 as of 2026-07-20.
gimli
MOREPENLAB stock AI analysis
MOREPENLAB Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
MOREPEN LAB. LTD is a small-cap stock in Healthcare. This Gimli page shows the latest available MOREPENLAB price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹58.23
1W return
-6.52%
1M return
+17.64%
3M return
+41.03%
6M return
+63.94%
1Y return
-6.88%
Market cap
₹3,190.73 cr
PE
33.63
PB
2.56
ROE
+7.80%
ROCE
+9.93%
RSI
54.88
Turnover
₹27.22 cr
Why it can matter in screens
- Momentum: MOREPENLAB is above 50DMA, above 200DMA; RSI is 54.88.
- Returns: 1D -1.14%, 1W -6.52%, 1M +17.64%, 3M +41.03%, 1Y -6.88%.
- Trend levels: 52W high ₹62.68, 52W low ₹33.68, off high -7.10%.
- Liquidity: latest turnover is ₹27.22 cr; volume vs 20D is +0.33%.
- Valuation/profitability: PE 33.63, PB 2.56, ROE +7.80%, ROCE +9.93%.
- Growth: 3Y sales CAGR +8.49%, 3Y profit CAGR +34.85%.
Quick Answers
Is MOREPENLAB above its 50DMA and 200DMA?
MOREPENLAB is above 50DMA, above 200DMA. The latest 50DMA is 50.79 and the latest 200DMA is 44.29.
What are MOREPENLAB PE, ROE and ROCE?
MOREPENLAB has PE 33.63, ROE +7.80%, and ROCE +9.93% in Gimli's latest available snapshot.
How has MOREPENLAB performed recently?
MOREPENLAB has returned +17.64% over 1 month, +41.03% over 3 months, and -6.88% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 484.72 cr | 32.91 cr | 15.74 cr | 0.28 |
| 2025-12-31 | 484.16 cr | 50.12 cr | 27.51 cr | 0.50 |
| 2025-09-30 | 411.58 cr | 61.16 cr | 40.87 cr | 0.75 |
| 2025-06-30 | 425.24 cr | 28.58 cr | 10.75 cr | 0.20 |
| 2025-03-31 | 465.85 cr | 46.85 cr | 20.32 cr | 0.35 |
| 2024-12-31 | 452.78 cr | 41.48 cr | n/a | nan |
| 2024-09-30 | 437.73 cr | 49.06 cr | n/a | 0.65 |
| 2024-06-30 | 455.22 cr | 55.05 cr | 36.17 cr | 0.71 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 1,805.69 cr | 172.77 cr | 94.88 cr | 1.73 |
| 2025-03-31 | 1,811.58 cr | 192.43 cr | 118.02 cr | 2.20 |
| 2024-03-31 | 1,682.13 cr | 172.60 cr | 96.16 cr | 1.88 |
| 2023-03-31 | 1,413.95 cr | 85.67 cr | 38.68 cr | 0.77 |
| 2022-03-31 | 1,459.50 cr | 156.77 cr | 101.06 cr | 1.94 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 1,936.12 cr | 31.19 cr | 207.86 cr | 1,247.09 cr |
| 2025-03-31 | 1,778.10 cr | 27.38 cr | 105.10 cr | 1,186.96 cr |
| 2024-03-31 | 1,293.21 cr | 16.95 cr | 29.00 cr | 847.23 cr |
| 2023-03-31 | 1,110.50 cr | 21.67 cr | 25.16 cr | 752.45 cr |
| 2022-03-31 | 1,070.05 cr | 15.80 cr | 18.57 cr | 578.10 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 32.64 cr | -127.90 cr | n/a |
| 2025-03-31 | 32.06 cr | -182.18 cr | n/a |
| 2024-03-31 | 73.37 cr | -7.96 cr | n/a |
| 2023-03-31 | -91.17 cr | -137.14 cr | n/a |
| 2022-03-31 | -60.24 cr | -127.61 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +35.65% | +1.46% | +1.28% | +0.00% | +61.59% | +0.00% |
| 2026-03-31 | +35.65% | +1.58% | +1.25% | +0.00% | +61.50% | +0.00% |
| 2025-12-31 | +35.65% | +1.62% | +1.25% | +0.00% | +61.46% | +0.00% |
| 2025-09-30 | +35.65% | +1.62% | +1.50% | +0.00% | +61.21% | +0.00% |
| 2025-06-30 | +35.65% | +1.72% | +1.51% | +0.00% | +61.11% | +0.00% |
| 2025-03-31 | +35.65% | +1.94% | +1.67% | +0.00% | +60.72% | +0.00% |
| 2024-12-31 | +35.65% | +2.22% | +1.64% | +0.00% | +60.47% | +0.00% |
| 2024-09-30 | +35.65% | +2.08% | +1.70% | +0.00% | +60.56% | +0.00% |
| 2024-08-05 | +35.65% | +7.72% | +2.90% | +0.00% | +53.72% | +0.00% |
| 2024-06-30 | +38.22% | +1.67% | +2.15% | +0.00% | +57.95% | +0.00% |
| 2024-03-31 | +38.22% | +1.85% | +2.15% | +0.00% | +57.77% | +0.00% |
| 2023-12-31 | +38.22% | +2.11% | +2.22% | +0.00% | +57.44% | +0.00% |
| 2023-09-30 | +38.22% | +1.29% | +2.28% | +0.05% | +58.20% | +0.00% |
| 2023-06-30 | +38.22% | +1.00% | +2.33% | +0.00% | +58.44% | +0.00% |
| 2023-03-31 | +38.22% | +0.96% | +2.93% | +0.00% | +57.88% | +0.00% |
| 2022-12-31 | +38.22% | +0.88% | +3.74% | +0.00% | +57.14% | +0.00% |
| 2022-09-30 | +38.22% | +1.16% | +3.98% | +0.00% | +56.63% | +0.00% |
| 2022-09-21 | +38.22% | +0.00% | +4.95% | n/a | n/a | +0.00% |
| 2022-06-30 | +36.74% | +0.00% | +5.03% | n/a | n/a | +0.00% |
| 2022-05-27 | +36.74% | +0.00% | +5.01% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 469,405.90 cr | 40.823336 | +14.71% | +15.52% |
| DIVISLAB | DIVI S LABORATORIES LTD | 194,269.92 cr | 75.650281 | +16.19% | +8.71% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 169,405.46 cr | 78.319677 | +17.18% | +42.14% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 128,040.28 cr | 65.380043 | +21.03% | +21.93% |
| CIPLA | CIPLA LTD | 116,452.52 cr | 30.005339 | +11.79% | -2.75% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 115,616.29 cr | 23.056854 | +17.93% | +17.85% |
| LUPIN | LUPIN LIMITED | 113,320.96 cr | 21.221472 | +26.83% | +28.27% |
| MAXHEALTH | MAX HEALTHCARE INS LTD | 107,290.40 cr | 74.382732 | +14.33% | -9.32% |
Try these prompts
- Analyze MOREPEN LAB. with valuation, momentum and industry peers
- Compare MOREPENLAB with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare MOREPENLAB with other Healthcare stocks
Data snapshot: 2026-07-20. Not investment advice.